---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-26-000043"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2026-06-11T12:02:57+00:00"
generated_at: "2026-06-11T12:05:15.552866+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Caribou reports vispa-cel 82% ORR, 17.1mo mPFS in 2L LBCL; CB-011 83% CR rate in MM

## Summary
- Vispa-cel in 27 optimized 2L LBCL patients: 82% ORR, 67% CR, 17.1 months median PFS.
- Vispa-cel safety: no GvHD, no grade 3+ ICANS; one grade 3+ CRS; one related death (IEC-HS).
- FDA aligned on ANTLER-3 phase 3 design for vispa-cel; ~250 CD19-naïve 2L LBCL patients, primary endpoint PFS.
- CB-011 in 12 BCMA-naïve r/r MM patients at RDE: 92% ORR, 83% ≥CR, 91% MRD negativity, 50% in ≥CR at 15 months.
- CB-011 case study: patient after 8 prior lines (incl. autologous CAR-T) achieved CR; dose expansion data expected H2 2026.

## SEC filing metadata
- accession: 0001619856-26-000043
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2026-06-11T12:02:57+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000043/0001619856-26-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000043/crbu-20260611.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-26-000043
- JSON: https://secwatch.observer/filing/0001619856-26-000043.json
- Plain text: https://secwatch.observer/filing/0001619856-26-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.